Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Clinical Cancer Research

• Publication date

  2012-06-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-12-0761PMID 22711709PMCID PMC3464009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies

  2012cited by this paper
• Functions of OATP1A and 1B transporters in vivo: insights from mouse models.

  2012cited by this paper
• Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.

  2012cited by this paper
• Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

  2012influential reference
• Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy

  2012cited by this paper
• Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

  2012cited by this paper
• Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters

  2011cited by this paper
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

  2011cited by this paper
• Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

  2011cited by this paper
• Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport.

  2011cited by this paper
• The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

  2011cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel

  2010cited by this paper
• Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.

  2010cited by this paper
• Development of a Cell-Based High-Throughput Assay to Screen for Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3

  2010cited by this paper
• Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations

  2010cited by this paper
• Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.

  2009cited by this paper
• Pharmacogenetic Pathway Analysis of Docetaxel Elimination

  2009influential reference
• Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.

  2009cited by this paper
• Impact of OATP transporters on pharmacokinetics

  2009cited by this paper
• Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia

  2008cited by this paper
• Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

  2008cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

  2008cited by this paper
• Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin

  2008cited by this paper
• Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1

  2008cited by this paper
• Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters

  2008cited by this paper
• Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3.

  2008cited by this paper
• The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3

  2007cited by this paper
• Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

  2007cited by this paper
• Supplementary Table S3

  2007cited by this paper
• Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

  2007cited by this paper
• Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

  2007cited by this paper
• A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

  2007cited by this paper
• Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.

  2007cited by this paper
• Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers

  2007cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

  2006cited by this paper
• Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

  2006cited by this paper
• Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

  2006cited by this paper
• Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics

  2006cited by this paper
• Clinical Pharmacokinetics of Docetaxel

  2006cited by this paper
• Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

  2006cited by this paper
• Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma

  2006cited by this paper
• Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics

  2005cited by this paper
• Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

  2005cited by this paper
• Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel

  2005cited by this paper
• Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17

  2005cited by this paper
• Letter to the Editors Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO 1 B 1 gene ( encoding OATP 1 B 1 )

  2005cited by this paper
• Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

  2004cited by this paper
• Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.

  2004cited by this paper
• High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

  2004cited by this paper
• In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes.

  2004cited by this paper
• Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches

  2003cited by this paper
• Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A

  2003cited by this paper
• Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation

  2003cited by this paper
• Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

  2002cited by this paper
• Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

  2002cited by this paper
• Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

  2001cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

  1996cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

  1996cited by this paper
• Plasma and Blood Volumes of Mouse Organs, As Determined with Radioactive Iodoproteins.∗

  1950cited by this paper

• Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.

  2026cites this paper
• Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

  2025cites this paper
• Coproporphyrin I as an in vitro fluorescent probe to measure OATP1B1 transport activity.

  2025cites this paper
• Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies.

  2025cites this paper
• Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective

  2025influential citation
• Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition.

  2024cites this paper
• Darolutamide does not interfere with OATP‐mediated uptake of docetaxel

  2024cites this paper
• Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy

  2023cites this paper
• Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark

  2022cites this paper
• Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.

  2022cites this paper
• Adding metabolic agents to prostate cancer therapy: Every rose has its thorn.

  2022cites this paper
• Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

  2022cites this paper
• Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective

  2022cites this paper
• The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature

  2022cites this paper
• PGPM_A_308531 613..652

  2022cites this paper
• Phenolsulfonphthalein as a surrogate substrate to assess altered function of the prostaglandin transporter SLCO2A1.

  2022cites this paper
• A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities

  2022cites this paper
• The Effect of Single Nucleotide Variations in the Transmembrane Domain of OATP1B1 on in vitro Functionality

  2021cites this paper
• Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.

  2021cites this paper
• Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships

  2021cites this paper
• Exploring pharmacogenetics of taxane-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships

  2021cites this paper
• Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans

  2021cites this paper
• Regulation of OATP1B1 Function by Tyrosine Kinase–mediated Phosphorylation

  2021cites this paper
• Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir

  2021cites this paper
• Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer

  2020cites this paper
• The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer

  2020cites this paper
• OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

  2020cites this paper
• Docetaxel loaded human serum albumin nanoparticles; synthesis, characterization, and potential of nuclear imaging of prostate cancer

  2020cites this paper
• Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

  2020cites this paper
• A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.

  2020cites this paper
• Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice.

  2020cites this paper
• Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations

  2020cites this paper
• Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

  2020cites this paper
• Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?

  2020cites this paper
• Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy

  2020cites this paper
• Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics

  2020influential citation
• Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug–drug interaction study

  2019cites this paper
• Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.

  2019cites this paper
• Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology

  2019influential citation
• ABC Family Transporters.

  2019cites this paper
• Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure

  2019cites this paper
• SLC Family Transporters.

  2019cites this paper
• Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib.

  2019cites this paper
• Liver Receptor Homolog-1 Regulates Organic Anion Transporter 2 and Docetaxel Pharmacokinetics

  2018cites this paper
• OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity

  2018cites this paper
• The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients

  2018cites this paper
• Circadian Clock Is Involved in Regulation of Hepatobiliary Transport Mediated by Multidrug Resistance-Associated Protein 2.

  2017cites this paper
• Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer

  2017cites this paper
• Advances in pharmacogenomic studies of docetaxel-a review

  2017cites this paper
• Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure

  2017cites this paper
• Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance

  2017cites this paper
• Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer

  2016cites this paper
• More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances

  2016cites this paper
• Pharmacokinetic effects of curcumin on docetaxel mediated by OATP1B1, OATP1B3 and CYP450s.

  2016cites this paper
• Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review

  2016cites this paper
• Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis

  2016cites this paper
• Pharmacological and Interventional Approaches for Optimizing Taxane Treatment

  2016cites this paper
• The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations

  2016cites this paper
• The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.

  2016cites this paper
• Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

  2016cites this paper
• MOLECULAR AND FUNCTIONAL INVESTIGATION OF CANCER-TYPE AND LIVER-TYPE VARIANTS OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3

  2015cites this paper
• Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

  2015cites this paper
• Inter-patient variability in docetaxel pharmacokinetics: A review.

  2015influential citation
• Extreme differences in SLCO1B3 functional polymorphisms in Roma and Hungarian populations.

  2015cites this paper
• Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel

  2015influential citation
• Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics

  2015cites this paper
• Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy

  2015cites this paper
• Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance

  2015influential citation
• Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.

  2015cites this paper
• Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

  2015cites this paper
• 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

  2015cites this paper
• Investigation of the association between genetics, drug exposure and statin-induced muscle toxicity

  2015cites this paper
• Therapeutics , Targets , and Chemical Biology In fl uence of Drug Formulation on OATP 1 B-Mediated Transport of Paclitaxel

  2014influential citation
• Characterisation of the Clinical Pharmacokinetics of Actinomycin D and the Influence of ABCB1 Pharmacogenetic Variation on Actinomycin D Disposition in Children with Cancer

  2014cites this paper
• Role of Membrane Transporters in Drug Delivery, Drug Disposition And Drug-Drug Interactions

  2014cites this paper
• Uptake Carriers and Oncology Drug Safety

  2014cites this paper
• Translational pharmacology and bioanalysis of oral taxanes

  2014cites this paper
• Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology

  2014influential citation
• Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations

  2014cites this paper
• 1+1=? Combinations and combination strategies in early cancer-drug development

  2014cites this paper
• Cancer du sein pendant la grossesse : interactions des taxanes avec le trophoblaste humain par une approche ex vivo et in vitro

  2014cites this paper
• Hepatic Uptake Transporters and Docetaxel Disposition in Mice—Letter

  2014cites this paper
• In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters

  2014cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2014cites this paper
• Influence of drug formulation on OATP1B-mediated transport of paclitaxel.

  2014cites this paper
• Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors

  2014cites this paper
• Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules

  2014influential citation
• Tumor-Specific Expression of Organic Anion-Transporting Polypeptides: Transporters as Novel Targets for Cancer Therapy

  2013cites this paper
• Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.

  2013cites this paper
• Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

  2013cites this paper
• Cancer Therapy : Preclinical Contribution of OATP 1 B 1 and OATP 1 B 3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013cites this paper
• Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma.

  2013cites this paper
• Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics

  2013cites this paper
• Pharmacokinetics and pharmacogenetics of actinomycin D in children with cancer

  2013cites this paper
• Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

  2013influential citation
• The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

  2013cites this paper
• Editors' pick 2012.

  2013cites this paper
• Identificación de marcadores predictivos de toxicidad y eficacia del paclitaxel: regulación y variación genética de la ß-tubulina y estudio de asociación del genoma completo

  2012cites this paper
• Targeting Organic Anion Transporting Polypeptides in Cancer to Improve Diagnostics and Therapy

  2012cites this paper
• Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.

  2012cites this paper